The TCM formula Xianling Lianxia, which is based on the therapeutic principle of “strengthening the body and eliminating pathogens,” enhances trastuzumab-mediated ADCC against HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.